Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs

Peter B. GilbertStatistical 2019 · DOI · arXiv

Abstract

Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men or transgender persons who have sex with men). Several challenges are posed to the optimal design of the sequel efficacy trials, including: (1) how to account for the evolving mosaic of effective prevention interventions that may be part of the trial design or standard of prevention; (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary "correlates of protection" results of each of the ongoing trials; and (3) how to define the primary objective of sequel efficacy trials if HIV-1 incidence is expected to be very low in all study arms such that a standard trial design has a steep opportunity cost.

Introduction: The Success Paradox in HIV Prevention

We are currently in a "golden age" of HIV prevention research, with several large-scale trials for vaccines and broadly neutralizing antibodies (bNAbs) underway. However, these trials face a looming "success paradox." As existing interventions like daily oral Pre-Exposure Prophylaxis (PrEP) and medical circumcision become the "standard of prevention," background HIV incidence rates successfully decline.

While this is a public health victory, it complicates the design of future "sequel" trials. It becomes ethically difficult to use a pure placebo group in future trials. Furthermore, as these tools successfully lower the number of new infections, the sample sizes required to statistically prove that a new intervention is even better become prohibitively large and expensive. This paper outlines a framework for designing scientifically rigorous and logistically feasible sequel trials.

Current Landmark Efficacy Trials

Two primary vaccine efficacy trials currently provide the foundation for future research: HVTN 702 and HVTN 705. These studies are testing different biological approaches to eliciting immunity.

HVTN 702: The South African Vaccine Trial

HVTN 702 is a large-scale study in South Africa testing a pox-protein prime-boost regimen. It aims to build upon the modest success of the RV144 trial in Thailand, adapted for the Clade C virus prevalent in the region.

Figure 1: Study design for the HVTN 702 trial in South Africa, comparing a pox-protein vaccine regimen against a placebo.

HVTN 705: The Mosaic Vaccine Trial

HVTN 705, also known as the Imbokodo study, is testing a "mosaic" vaccine designed to provide broad protection against various HIV strains globally. This trial focuses on women in several sub-Saharan African countries.

Figure 3: Study design for the HVTN 705 trial, testing an Ad26-based mosaic vaccine regimen in sub-Saharan African women.

Methodological Framework for Sequel Trials

To address the challenges of declining incidence and evolving standards of care, three primary randomized trial designs are proposed for studying a new intervention (A) while accommodating a proven intervention (B):

  • Layer Design: Facilitated access to B is provided to all participants. The trial compares A vs. a placebo for A. This is efficient but assumes A and B are distinct enough in modality (e.g., a vaccine vs. a daily pill).
  • Compare Design: Participants are randomized to receive either A or B. This often leads to non-inferiority trials, which require proving that A is "not much worse" than B. This can increase required sample sizes by 4 to 5 times compared to layer designs.
  • Combine Design: Compares A + B vs. B alone. This is ideal for testing if a new vaccine adds a meaningful "layer" of protection on top of existing PrEP.

Statistical Science and Correlates of Protection

The most critical factor for sequel design is identifying a "correlate of protection" (CoP). If the first trial proves that a specific host immunological marker predicts immunity, the sequel trial might only need to prove the new intervention reaches that level (immuno-bridging), rather than waiting years for infections to occur.

Furthermore, the paper discusses counterfactual placebo analysis, which uses statistical modeling to estimate what the infection rate would have been without any intervention. While this approach is fraught with risks for bias due to unverifiable assumptions, it may become a necessary tool when traditional placebo arms are no longer feasible. Reliability would require new techniques, such as using other STIs as validated exposure markers or establishing permanent sentinel surveillance cohorts.

Conclusion

The transition from current efficacy trials to their sequels requires a shift in statistical thinking. By leveraging correlates of protection, exploring novel randomized designs, and refining counterfactual modeling, the research community can continue to innovate even as the landscape of HIV prevention successfully evolves.

Summary updated

Abstract

Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men or transgender persons who have sex with men). Several challenges are posed to the optimal design of the sequel efficacy trials, including: (1) how to account for the evolving mosaic of effective prevention interventions that may be part of the trial design or standard of prevention; (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary "correlates of protection" results of each of the ongoing trials; and (3) how to define the primary objective of sequel efficacy trials if HIV-1 incidence is expected to be very low in all study arms such that a standard trial design has a steep opportunity cost. After summarizing the ongoing trials, I discuss statistical science considerations for sequel efficacy trial designs, both generally and specifically to each trial listed above. One conclusion is that the results of "correlates of protection" analyses, which ascertain how different host immunological markers and HIV-1 viral features impact HIV-1 risk and prevention efficacy, have an important influence on sequel trial design. This influence is especially relevant for the monoclonal antibody trials because of the focused pre-trial hypothesis that potency and coverage of serum neutralization constitutes a surrogate endpoint for HIV-1 infection. Another conclusion is that while assessing prevention efficacy against a counterfactual placebo group is fraught with risks for bias, such analysis is nonetheless important and study designs coupled with analysis methods should be developed to optimize such inferences. I draw a parallel with non-inferiority designs, which are fraught with risks given the necessity of making unverifiable assumptions for interpreting results, but nevertheless have been accepted when a superiority design is not possible and a rigorous/conservative non-inferiority margin is used. In a similar way, counterfactual placebo group efficacy analysis should use rigorous/conservative inference techniques that formally build in a rigorous/conservative margin to potential biases that could occur due to departures from unverifiable assumptions. Because reliability of this approach would require new techniques for verifying that the study cohort experienced substantial exposure to HIV-1, currently it may be appropriate as a secondary objective but not as a primary objective.
BibTeX
@inproceedings{gilbert2019ongoing,
  author = {Peter B. Gilbert},
  title = {{Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs}},
  booktitle = {Statistical},
  year = {2019},
  doi = {10.1515/scid-2019-0003},
}
Figure